Skip to main content
Premium Trial:

Request an Annual Quote

Scimagix Integrates Image Management Software with Amersham Platform

NEW YORK, Nov. 6-In a development partnership with Amersham Biosciences, Scimagix will retool its SIMS image management database for use with Amersham's IN Cell Analyzer 3000 screening platform, the company said yesterday.

 

Amersham's system can be used to monitor cellular processes as they are affected by drug candidates. It is designed to generate up to 30,000 cellular images per day.

 

Scimagix plans to adapt its database system so that image, annotation and analysis data generated by multiple Amersham platforms in one company can be integrated and organized in an automated fashion. Drug development researchers would be able to access cellular images and data with a web-based browser.

 

Financial details of this agreement were not reported.

 

According to Scimagix, one bottleneck in drug development arises because cell-based screening data tends to be isolated and fragmented. Its product is designed to centralize image-based data storage and mining process.

 

Scimagix is an informatics company based in San Mateo, Calif.

 

For further information, see the company website.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more